1. Home
  2. MDRR vs CMMB Comparison

MDRR vs CMMB Comparison

Compare MDRR & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Medalist Diversified REIT Inc.

MDRR

Medalist Diversified REIT Inc.

HOLD

Current Price

$11.62

Market Cap

18.3M

Sector

Real Estate

ML Signal

HOLD

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

N/A

Current Price

$2.42

Market Cap

19.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MDRR
CMMB
Founded
2015
2004
Country
United States
Israel
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.3M
19.9M
IPO Year
2015
2023

Fundamental Metrics

Financial Performance
Metric
MDRR
CMMB
Price
$11.62
$2.42
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
2.8K
112.3K
Earning Date
03-02-2026
05-21-2026
Dividend Yield
2.43%
N/A
EPS Growth
N/A
101.67
EPS
4.74
0.04
Revenue
$10,396,618.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.53
$64.50
Revenue Growth
6.79
N/A
52 Week Low
$9.47
$1.35
52 Week High
$14.52
$3.55

Technical Indicators

Market Signals
Indicator
MDRR
CMMB
Relative Strength Index (RSI) 47.67 52.40
Support Level $11.01 $1.49
Resistance Level $12.23 $2.88
Average True Range (ATR) 0.35 0.22
MACD -0.00 -0.05
Stochastic Oscillator 23.68 14.19

Price Performance

Historical Comparison
MDRR
CMMB

About MDRR Medalist Diversified REIT Inc.

Medalist Diversified Inc owns ten investment properties comprised of three retail properties, three flex/industrial properties, and four STNL properties, including the Tesla Pensacola Property. Through its subsidiary, the company sponsors Delaware Statutory Trusts (DSTs) that provide accredited investors access to institutional-quality real estate with the transparency and governance of a public company. The company has three reportable segments, consisting of retail center properties, flex center properties, and STNL properties. The company generates the majority of its revenue from the Retail Center Property.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Share on Social Networks: